Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sunesis Pharmaceuticals Inc (SNSS): Cormorant Asset Management Reports New 5.14% Stake

Page 1 of 10

Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) has a new shareholder in the form of Bihua Chen‘s Cormorant Asset Management. As per a new 13G filing with the Securities and Exchange Commission, the fund has acquired 1 million common shares of the company, which represent 5.14% of the float. According to its 13F filing for the end of the second quarter, the fund held no shares of Sunesis Pharmaceuticals at the end of June.

As its name suggests, Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) is a clinical-stage biopharmaceutical company that is working on the production of its pipeline of oncology therapeutics. Cormorant’s acquisition of shares comes a couple of weeks after the company announced a spot secondary offering of 4.936 million shares at $3.85 per share, which could be what opened the door for Cormorant to build its position. Over the past 12 months, the company’s stock has lost 29.92%. For the second quarter of 2016, Sunesis Pharmaceuticals reported a loss per share of $0.12 and revenue of $0.61 million, both of which missed expectations of a loss per share of $0.10 and revenue of $1.04 million.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

11 hedge funds from within Insider Monkey’s database reported having long positions in Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) as of the end of June, up by two from a quarter earlier. Among the investors with the largest positions were Jeffrey Jay and David Kroin’s Great Point Partners (8.17 million shares), William Leland Edwards’ Palo Alto Investors (6.97 million shares), Julian Baker and Felix Baker’s Baker Bros. Advisors (4.45 million shares), and Richard Driehaus’ Driehaus Capital (1.95 million shares).

Follow Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)
Trade (NASDAQ:SNSS) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Cormorant Global Healthcare Master Fund 0 831,500 0 831,500 831,500 4.28%
Cormorant Global Healthcare GP 0 831,500 0 831,500 831,500 4.28%
Cormorant Asset Management 0 1,000,000 0 1,000,000 1,000,000 5.14%
Bihua Chen 0 1,000,000 0 1,000,000 1,000,000 5.14%

Bihua Chen
Bihua Chen
Cormorant Asset Management

Page 1 of 10 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL
OMB Number:3235-0145
Expires: February 28, 2009
Estimated average burden
hours per response… 10.4
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Sunesis Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
867328502
(CUSIP Number)
October 19, 2016
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
___________________________________
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)
Trade (NASDAQ:SNSS) Now!
Page 1 of 10
Loading Comments...